THALES / EXAIL - WHY A SAFRAN COUNTER IS (ALMOST) DEAD ON ARRIVAL
Thales signs binding agreement with Gorge family for 35.51 pct block in Exail Technologies at EUR 134/shr - EV EUR 3.9bn - 44 pct premium
to unaffected (Jun 25). Mandatory tender for 100 pct + ODIRNANE to follow via AMF. Block closing 3Q26 - tender close early 2028 latest.
Safran was at EUR 128.5 last week. Can they come back?
Technically yes - practically no.
1 - THE BLOCK IS THE POISON PILL
French family block sale = no fiduciary out. Once the SPA is signed, the Gorge family cannot flip to a higher bid. Conditions are normally
limited to regulatory clearance. Safran's window was BEFORE signing.
2 - A TOPPING BID IS ECONOMICALLY IRRATIONAL
Post-closing Thales sits on 35.51 pct - above the 33.3 pct threshold. A competing AMF offer (min +2 pct = EUR 136.7) would only capture the
float and leave Thales as entrenched blocking minority - no squeeze- out (90 pct), no merger, no EGM control. Nobody pays a 45 pct premium to cohabit with Thales.
3 - RESIDUAL DISRUPTION VECTORS (DESCENDING PLAUSIBILITY)
- Antitrust: overlap in sonar / underwater warfare / MCM (Thales UWS vs ex-iXblue / ECA). The "early 2028 at the latest" tender close
telegraphs a long regulatory review. If remedies kill the deal, Safran re-enters as white knight. Low probability, non-zero.
- Political: DGA / APE arbitration of the defense landscape. The signing suggests Paris has already blessed Thales.
- ODIRNANE / minority agitation: noise, not a blocker.
TRADING TAKE
At or below EUR 134 the market pays zero for counter-bid optionality
- correctly. Any premium above deal price prices the antitrust- collapse-then-Safran path - we would fade it. Residual trades: the
carry to a 2027-28 tender close, and Thales itself - year-one EPS accretion claimed at a 44 pct premium implies a synergy number worth
stress-testing against Exail's revenue base.
LC / Graham Advisors